Eyenovia, Inc. EYEN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

36/100

0/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Eyenovia, Inc. (EYEN) , 前瞻盈利收益率 18.52%.

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
前瞻市盈率 5.4

SharesGrow 综合评分： 34/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score

36/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✗

未來

20/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

护城河

58/100

→ Income

成长

58/100

→ Income

✗

收入

10/100

→ Income

估值概览 — EYEN

估值倍数

P/E (TTM)0.0

前瞻 P/E5.4

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$0.00

前瞻 EPS（预估）$1.40

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

Forward Earnings Yield18.52%

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2016	$-0.36	$0.00	$-3.53M	-
2017	$-0.52	$0.00	$-5.13M	-
2018	$-1.82	$0.00	$-17.25M	-
2019	$-1.46	$0.00	$-20.99M	-
2020	$-0.94	$2M	$-19.69M	-984.6%
2021	$-0.49	$14M	$-12.99M	-92.8%
2022	$-0.82	$0.00	$-27.73M	-
2023	$-0.66	$3.79K	$-27.26M	-719859.9%
2024	$-57.30	$57.34K	$-49.82M	-86888.6%
2025	$0.00	$813.46M	$-47B	-5777.7%